Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...
Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said ...
Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...
CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical ...
CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical trials ...
BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...
The primary objective is to evaluate the safety of CLN-978 for the treatment of active moderate to severe SLE, with secondary ...
After hours: October 18 at 4:02 PM EDT Loading Chart for CGEM ...
Another is Cullinan Therapeutics, whose CLN-978 candidate is due to start trials in the coming months in systemic lupus erythematosus (SLE) and rheumatoid arthritis. Ono Pharma and Boehringer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback